Multiple Sclerosis Treatment

ZINCARE

M. Chomba

ECTRIMS 2024 Insights: Real-World Evidence on Infection-Related Hosp…

Afagh Garjani

ECTRIMS 2024 Insights: Increased Brain Age Is Associated With Clinic…

Lonneke Bos

Aberrant Iron Deposition in the Progressive MS Spinal Cord Relates t…

Marco Pisa

COVID-19 & Multiple Sclerosis: Can Immunosuppressive Therapy Decreas…

Gavin Giovannoni

The Role of B Cells in Progressive MS and the Long-term Effects of B…

The France Foundation

J. Berger

Effectiveness of Tixagevimab/Cilgavimab (Evusheld) in AntiCD20-Treat…

Dominika Stastna

Breaking Down Common But Complicated Questions in MS: Updates on Bio…

Women Neurologists Group (WNG)

E. M. Schorr

Paramagnetic Rim Lesions Predict Greater Long-Term Relapse Rates and…

Jack A. Reeves

Dry Needling & High Tech Mobility Devices for the Lower Extremity

Cleveland Clinic Neurological Institute

A. Gaglione

Therapeutic Approaches for Multiple Sclerosis: What We Know and What…

Cleveland Clinic Nevada

C. Hersh

Inflammatory Management in Multiple Sclerosis: The Complementary Med…

Women Neurologists Group (WNG)

M. Rensel

The Connection Between Viruses and Other Factors Contributing to the…

The France Foundation

M. Levy

Neural effects of fatigue on cognition in relapsing MS detected by m…

2023 Conference Coverage

A. Memon

ECTRIMS 2024 Insights: The Definition of Progression Independent of …

Emilio Portaccio

Rapid Fire Research Update: Treatment Approach Trials in MS

Cleveland Clinic Neurological Institute

M. Mcginley

Multiple Sclerosis for the Non-Neurologist

Providence Swedish

J. D. Bowen

Practical Challenges Managing MS: Recent Advances in the Understandi…

The France Foundation

S. Newsome, J. Oh, L. Fox

MS Relapse Redefined: Distinguishing True Relapses from Pseudoexacer…

Stephen Krieger

Highlights on Multiple Sclerosis: Topographical Model of MS and JC V…

2023 Conference Coverage

S. Krieger